• Publications
  • Influence
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
Activating mutations of the serine threonine kinase v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) are frequent in benign and malignant human tumors and are emerging as an important biomarker.Expand
  • 404
  • 20
  • Open Access
EANO guidelines for the diagnosis and treatment of meningiomas.
Although meningiomas are the most common intracranial tumours, the level of evidence to provide recommendations for the diagnosis and treatment of meningiomas is low compared with other tumours suchExpand
  • 210
  • 14
The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry
In Austria, registration of malignant brain tumours is legally mandatory, whereas benign and borderline tumours are not reported. The Austrian Brain Tumour Registry (ABTR) was initiated under theExpand
  • 130
  • 9
Interlaboratory Comparison of Assessments of Alzheimer Disease-Related Lesions: A Study of the BrainNet Europe Consortium
Abstract This interlaboratory study evaluated the reproducibility of the assessments of neuritic plaques and neurofibrillary tangles (NFTs)-the hallmark lesions of Alzheimer disease-and compared theExpand
  • 95
  • 4
Clinicoradiological features of rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle: report of four cases and literature review
Background Rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle is a recently characterized rare tumor entity. Despite benign histological features and a reported favorable postoperativeExpand
  • 47
  • 4
Quantitative evidence for early metastatic seeding in colorectal cancer
Both the timing and molecular determinants of metastasis are unknown, hindering treatment and prevention efforts. Here we characterize the evolutionary dynamics of this lethal process by analyzingExpand
  • 62
  • 4
Interlaboratory comparison of IDH mutation detection
Isocitrate dehydrogenase (IDH) mutational testing is becoming increasingly important. For this, robust and reliable assays are needed. We tested the variation of results between six laboratories ofExpand
  • 58
  • 3
Neurocognitive training in patients with high-grade glioma: a pilot study
Although their neurocognitive performance is one of the major concerns of patients with high-grade gliomas (HGG) and although neurocognitive deficits have been described to be associated withExpand
  • 57
  • 3
  • Open Access
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
The oncometabolite (R)-2-hydroxyglutarate (R-2-HG) produced by isocitrate dehydrogenase (IDH) mutations promotes gliomagenesis via DNA and histone methylation. Here, we identify an additionalExpand
  • 64
  • 3
Imaging ex vivo healthy and pathological human brain tissue with ultra-high-resolution optical coherence tomography.
The ability of ultra-high-resolution optical coherence tomography (UHR OCT) to discriminate between healthy and pathological human brain tissue is examined by imaging ex vivo tissue morphology ofExpand
  • 76
  • 2